CLYM

CLYM stock has trended upwards by 91.44% in the past six months and significantly increased by 456.44% and 563.2% over the past year, with a 52-week range of $1.54 to $18.33. Specific events include a director selling 100,000 shares on September 17, 2026, the largest daily stock move of +30.4% on December 12, 2025, and the announcement of CLYM116 Phase 1 data demonstrating prolonged half-life and best-in-class APRIL suppression on September 3, 2026. The company also anticipates initiating dosing for the CLYM116 Phase 2 trial in IgA nephropathy in Q3 2026.